These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28075544)

  • 21. Targeting of the diabetes prevention program leads to substantial benefits when capacity is constrained.
    Olchanski N; van Klaveren D; Cohen JT; Wong JB; Ruthazer R; Kent DM
    Acta Diabetol; 2021 Jun; 58(6):707-722. PubMed ID: 33517494
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study.
    Moffatt S; Wildman J; Pollard TM; Gibson K; Wildman JM; O'Brien N; Griffith B; Morris SL; Moloney E; Jeffries J; Pearce M; Mohammed W
    Public Health Res (Southampt); 2023 Mar; 11(2):1-185. PubMed ID: 37254700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of a Stepwise Approach vs Standard Care for Diabetes Prevention in India.
    Islek D; Weber MB; Ranjit Mohan A; Mohan V; Staimez LR; Harish R; Narayan KMV; Laxy M; Ali MK
    JAMA Netw Open; 2020 Jul; 3(7):e207539. PubMed ID: 32725244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study.
    Gillett M; Brennan A; Watson P; Khunti K; Davies M; Mostafa S; Gray LJ
    Health Technol Assess; 2015 May; 19(33):1-80. PubMed ID: 25947106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes.
    Roberts S; Barry E; Craig D; Airoldi M; Bevan G; Greenhalgh T
    BMJ Open; 2017 Nov; 7(11):e017184. PubMed ID: 29146638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of alternative thresholds of the fasting plasma glucose test to identify the target population for type 2 diabetes prevention in adults aged ≥45 years.
    Zhuo X; Zhang P; Kahn HS; Gregg EW
    Diabetes Care; 2013 Dec; 36(12):3992-8. PubMed ID: 24135386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
    Annemans L; Marbaix S; Webb K; Van Gaal L; Scheen A
    Clin Drug Investig; 2010; 30(2):133-42. PubMed ID: 20067331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Benchmarking the Cost-Effectiveness of Interventions Delaying Diabetes: A Simulation Study Based on NAVIGATOR Data.
    Leal J; Reed SD; Patel R; Rivero-Arias O; Li Y; Schulman KA; Califf RM; Holman RR; Gray AM
    Diabetes Care; 2020 Oct; 43(10):2485-2492. PubMed ID: 32796009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness of a Short Message Service Intervention to Prevent Type 2 Diabetes from Impaired Glucose Tolerance.
    Wong CK; Jiao FF; Siu SC; Fung CS; Fong DY; Wong KW; Yu EY; Lo YY; Lam CL
    J Diabetes Res; 2016; 2016():1219581. PubMed ID: 26798647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of a brief theory-based health promotion intervention among adults at high risk of type 2 diabetes: One-year results from a randomised trial in a community setting.
    Juul L; Andersen VJ; Arnoldsen J; Maindal HT
    Prim Care Diabetes; 2016 Apr; 10(2):111-20. PubMed ID: 26259517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An economic evaluation for prevention of diabetes mellitus in a developing country: a modelling study.
    Liu X; Li C; Gong H; Cui Z; Fan L; Yu W; Zhang C; Ma J
    BMC Public Health; 2013 Aug; 13():729. PubMed ID: 23919839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.
    Icks A; Rathmann W; Haastert B; Gandjour A; Holle R; John J; Giani G;
    Diabet Med; 2007 May; 24(5):473-80. PubMed ID: 17381502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Cost-Effectiveness of Lifestyle Interventions for Preventing Diabetes in a Health Resource-Limited Setting.
    Ma J; Wan X; Wu B
    J Diabetes Res; 2020; 2020():7410797. PubMed ID: 32352016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achievable cost saving and cost-effective thresholds for diabetes prevention lifestyle interventions in people aged 65 years and older: a single-payer perspective.
    Anderson JM
    J Acad Nutr Diet; 2012 Nov; 112(11):1747-54. PubMed ID: 23102174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SLIMMER: a randomised controlled trial of diabetes prevention in Dutch primary health care: design and methods for process, effect, and economic evaluation.
    Duijzer G; Haveman-Nies A; Jansen SC; ter Beek J; Hiddink GJ; Feskens EJ
    BMC Public Health; 2014 Jun; 14():602. PubMed ID: 24928217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of Including Costs and Outcomes of Dementia in a Health Economic Model to Evaluate Lifestyle Interventions to Prevent Diabetes and Cardiovascular Disease.
    Breeze P; Thomas C; Thokala P; Lafortune L; Brayne C; Brennan A
    Med Decis Making; 2020 Oct; 40(7):912-923. PubMed ID: 32951510
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Behavioural interventions to promote physical activity in a multiethnic population at high risk of diabetes: PROPELS three-arm RCT.
    Khunti K; Griffin S; Brennan A; Dallosso H; Davies M; Eborall H; Edwardson C; Gray L; Hardeman W; Heathcote L; Henson J; Morton K; Pollard D; Sharp S; Sutton S; Troughton J; Yates T
    Health Technol Assess; 2021 Dec; 25(77):1-190. PubMed ID: 34995176
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of the SLIMMER diabetes prevention intervention in Dutch primary health care: economic evaluation from a randomised controlled trial.
    Duijzer G; Bukman AJ; Meints-Groenveld A; Haveman-Nies A; Jansen SC; Heinrich J; Hiddink GJ; Feskens EJM; de Wit GA
    BMC Health Serv Res; 2019 Nov; 19(1):824. PubMed ID: 31711499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Offering a lifestyle intervention to women of premenopausal age as primary prevention for cardiovascular disease? - assessing its cost-effectiveness.
    Gao L; Moodie M
    Int J Behav Nutr Phys Act; 2022 Dec; 19(1):152. PubMed ID: 36517831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.